MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

11.79 -2.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.61

Максимум

12.02

Ключови измерители
By Trading Economics
Приходи	3.9M -30M
Продажби	5M 52M
Марж на печалбата	-56.881
Служители	619
EBITDA	-3.3M -30M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-2.73% downside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	629M 1.8B
Предишно отваряне	14.11
Предишно затваряне	11.79

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11.07.2025 г., 16:03 ч. UTC

Печалби

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11.07.2025 г., 16:02 ч. UTC

Печалби

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11.07.2025 г., 16:01 ч. UTC

Печалби

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11.07.2025 г., 16:00 ч. UTC

Печалби

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11.07.2025 г., 15:59 ч. UTC

Печалби

BASF Cuts 2025 Earnings View

11.07.2025 г., 15:58 ч. UTC

Печалби

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11.07.2025 г., 15:57 ч. UTC

Печалби

BASF 2Q EBIT Before Special Items EUR810M

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF 2Q Sales Fell 2.1% on Year

11.07.2025 г., 15:53 ч. UTC

Печалби

BASF 2Q Sales EUR15.77B

11.07.2025 г., 15:52 ч. UTC

Печалби

BASF: This Was in Line With Consensus Estimates

11.07.2025 г., 15:52 ч. UTC

Печалби

BASF 2Q Ebitda Before Special Items EUR1.77B

11.07.2025 г., 15:49 ч. UTC

Печалби

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11.07.2025 г., 15:41 ч. UTC

Пазарно говорене

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

-2.73% надолу

12-месечна прогноза

Среден 11.75 USD -2.73%

Висок 15 USD

Нисък 9 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.